Randomized clinical trials in melanoma

Surgical Oncology Clinics of North America

Volumn 11, Issue 1, 2002, Pages 23-52

  Spanknebel, Kathryn ^a   Temple, Larissa ^a   Hiotis, Spiros ^a   Yeh, Alice ^a   Coit, Daniel G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BCG VACCINE; BIOLOGICAL RESPONSE MODIFIER; CISPLATIN; DACARBAZINE; GANGLIOSIDE GM2; GM2 KLH QS 21; GM2 KLH QS 21 VACCINE; MELANOMA VACCINE; MELPHALAN; NITROSOUREA DERIVATIVE; PLACEBO; PLATINUM DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; TAMOXIFEN; TAXANE DERIVATIVE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VACCINA MELANOMA ONCOLYSATE; VINBLASTINE; VINCA ALKALOID;

CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; HUMAN; HYPERTHERMIC THERAPY; MELANOMA; META ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; REVIEW; VACCINATION;

EID: 0036136775     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1055-3207(03)00074-7     Document Type: Review

References (35)

1. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial
2. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger
3. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial
4. Results of adjuvant interferon study in WHO Melanoma Programme
5. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial
6. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma
7. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen
8. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma
9. Phase III randomized trial of cisplatin, vinblastine and dacarbazine (CVD) plus interleukin-2 (IL2) and interferon-alpha-2b (INF) versus CVD in patients with metastatic melanoma
10. A phase III randomized trial of dacarbazine and carboplatin with and without tamoxifen in the treatment of patients with metastatic melanoma
11. Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases
12. The pathology of melanotic growths in relation to their operative treatment
13. Interferon alfa-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European organization for research and treatment of cancer melanoma cooperative group
14. High- and low-dose interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C 9190
15. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The eastern cooperative oncology group trial EST 1684
16. Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial
17. Improved survival in stage III melanoma patients with GM2 antibodies: A randomized trial of adjuvant vaccination with GM2 ganglioside
18. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma
19. Validation of the accuracy of intraoperative lymphatic mapping and sentinel lymphadenectomy for early-stage melanoma: A multicenter trial
20. The malignant melanoma of the skin. New theories based on a study of 500 cases
21. Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma
22. Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: Randomized study by the Swedish melanoma study group
23. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer
24. Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma
25. Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma
26. Inefficacy of immediate node dissection in stage I melanoma of the limbs
27. Stage I melanoma of the limbs. Immediate versus delayed node dissection
28. Delayed regional lymph node dissection in stage I melanoma of the skin of the lower extremities
29. Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm
30. Narrow excision (1-cm margin): A safe procedure for thin cutaneous melanoma
31. Phase II study of vindesine and dacarbazine with or without non-specific stimulation of the immune system in patients with metastatic melanoma
32. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: The final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial
33. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma
34. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: Second interim analysis of data from a phase III, multi-institutional trial
35. Favorable clinical responses in subsets of patients from a randomized, multi-institutional melanoma vaccine trial